Comparing two medicines for anemia in kidney dialysis
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study compares two similar medicines used to treat anemia (low red blood cells) in people with advanced kidney disease who are on dialysis. The goal is to see if both work equally well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 5 chronic kidney disease (kidney failure) and are receiving hemodialysis.
- You are willing and able to provide consent to participate.
- You do not have another severe chronic disease.
- You have no history of pure red cell aplasia (a rare condition where the body stops making red blood cells).
- You do not have antibodies against erythropoietin (a protein that helps make red blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study compares two anemia medicines for people with chronic kidney disease (CKD) who are not on dialysis. It aims to find a more convenient pill option (daprodustat) versus a commonly used injection (epoetin alfa).
This study tests whether a medication called erythropoietin (a hormone that helps your body make red blood cells) can improve hemoglobin levels in people on dialysis. It also looks at whether metabolic syndrome (a group of conditions like high blood pressure and high blood sugar) makes the medicine less effective.
This study tests an experimental medicine for anemia in people with kidney disease who are on dialysis. It aims to see if it can help raise blood counts safely compared to standard treatments.
This trial tests a new medicine (NANOKINE) that helps your body make red blood cells, compared to a well-known drug (Eprex). It is for healthy men to see how safe it is and how it works in the body. If you qualify, you might help develop a better option for treating anemia.
This trial tests a new medicine called pegmolesatide for people with chronic kidney disease and anemia. It compares switching to this new medicine versus staying on current treatments, to see if it is safe and works well.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.